

Vitamin D Metabolism and Rickets in Domestic Animals : A Review

K. E. Dittmer and K. G. Thompson

Vet Pathol 2011 48: 389 originally published online 15 July 2010

DOI: 10.1177/0300985810375240

The online version of this article can be found at:

<http://vet.sagepub.com/content/48/2/389>

Published by:



<http://www.sagepublications.com>

On behalf of:

[American College of Veterinary Pathologists](#), [European College of Veterinary Pathologists](#), & the [Japanese College of Veterinary Pathologists](#).

Additional services and information for *Veterinary Pathology Online* can be found at:

Email Alerts: <http://vet.sagepub.com/cgi/alerts>

Subscriptions: <http://vet.sagepub.com/subscriptions>

Reprints: <http://www.sagepub.com/journalsReprints.nav>

Permissions: <http://www.sagepub.com/journalsPermissions.nav>

>> [Version of Record](#) - Mar 8, 2011

[OnlineFirst Version of Record](#) - Jul 15, 2010

[What is This?](#)

Vitamin D Metabolism and Rickets in Domestic Animals: A Review

Veterinary Pathology
48(2) 389-407
© The American College of
Veterinary Pathologists 2011
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/0300985810375240
http://vet.sagepub.com



K. E. Dittmer¹ and K. G. Thompson¹

Abstract

Rickets and osteomalacia are increasing in prevalence in people because of cultural practices, breast-feeding, decreased sun exposure, and increased sunscreen usage. Several hereditary forms of rickets owing to either renal phosphate wasting or defects in vitamin D metabolism are also reported in people. Rickets is well recognized in domestic animals, but published reports are not always supported by microscopic findings, and diagnoses based on clinical signs and radiology are unreliable. Most cases in domestic animals are caused by dietary deficiency of either vitamin D or phosphorus, but occasional inherited forms are reported in pigs, sheep, cats, and dogs. There is variation between species in susceptibility to dietary vitamin D and phosphorus deficiency and in the ability to manufacture vitamin D in their skin. A number of mouse models have been discovered or created to study human skeletal diseases and skeletal homeostasis. With the discovery that vitamin D is involved in not only calcium and phosphorus homeostasis but also in the immune system and cancer, there is great potential for new and existing animal models to generate valuable information about vitamin D and its many functions. This review presents an overview of vitamin D metabolism and rickets in domestic and laboratory animals and makes comparisons where appropriate with the disease in humans.

Keywords

bone, rickets, vitamin D, phosphorus, genetic diseases

Rickets is a classic metabolic bone disease of humans and animals, first described in the first and second centuries.^{158,165} With the discovery that vitamin D could prevent rickets, the prevalence of this disease in developed countries plummeted; however, it still occurs. In fact, the prevalence of rickets and vitamin D insufficiency is increasing in people of all ages in the developed world, due in part to decreased sunlight exposure and widespread sunscreen usage.⁸⁸ The disease is well recognized in animals, but published reports are uncommon and sometimes confusing.

The pathogenesis of rickets involves impaired mineralization of physal and epiphyseal cartilage during endochondral ossification and of newly formed osteoid. Most cases in domestic animals are caused by dietary deficiency of either vitamin D or phosphorus, but occasional inherited forms are reported.^{109,200} Osteomalacia is caused by a failure of newly formed osteoid to mineralize, but it occurs in adults after closure of growth plates.¹⁰⁹

In this article, we review vitamin D metabolism and rickets, with reference to the disease in domestic animals but presenting comparison with the disease in humans where appropriate.

Biology of Vitamin D

Activation of Vitamin D

Vitamin D is available from two sources: isomerization of 7-dehydrocholesterol (7-DHC) in the skin to vitamin D₃

following exposure to ultraviolet light or from ingestion of vitamin D₂ or D₃ in the diet. Only a few foods, including cod liver oil and fatty fish such as salmon and sardines, naturally contain high concentrations of vitamin D₃.⁴⁹ Vitamin D₂ is present in certain plants owing to conversion of ergosterol to vitamin D₂ by ultraviolet light.⁴⁰

Ultraviolet light in the 270- to 315-nm range is required for the conversion of 7-DHC in the skin to previtamin D₃, which then undergoes thermal isomerization to vitamin D₃ over the course of 3 days.^{87,100} The formation efficiency of vitamin D₃ in the skin is influenced by skin pigmentation and ultraviolet light intensity.^{13,87} Melanin vies with 7-DHC for ultraviolet photons, and a longer time in sunlight is required for maximum previtamin D₃ formation in dark-skinned animals.⁸⁷ The intensity of ultraviolet light that reaches the skin of the animal depends on latitude and altitude. Ultraviolet radiation is less at higher latitudes, particularly during winter, when daylight hours are low.^{159,213} When the altitude of the sun is less

¹ Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Palmerston North, New Zealand

Corresponding Author:

K.E. Dittmer, Institute of Veterinary, Animal and Biomedical Sciences, Tennant Drive, Private Bag 11 222, Massey University, Palmerston North, New Zealand
Email: K.E.Dittmer@massey.ac.nz

than 35°, as occurs during winter at latitudes of 31° or higher, there is insufficient penetration of ultraviolet light to convert 7-DHC to previtamin D₃.¹³ At high altitude, ultraviolet radiation may be intense, and animals may be exposed to excessive or prolonged exposure to sun.⁹⁰ In these situations, previtamin D₃ photoisomerizes to the biologically inert tachysterol and lumisterol, which are sloughed off with keratinocytes during normal skin turnover.⁸⁷

Species vary in their ability to form vitamin D₃ in their skin. For example, exposure of dogs and cats to ultraviolet light does not significantly increase dermal vitamin D₃ concentration.⁹² In contrast, similar irradiation of rats leads to a 40-fold increase in vitamin D₃.⁹² This presumably relates to the presence of 7-DHC-Δ⁷-reductase, an enzyme capable of degrading 7-DHC, in the skin of cats.¹⁴⁵ Not surprisingly, a study in Australia demonstrated that, unlike other species, dogs did not show seasonal variation in serum 25-hydroxyvitamin D (25(OH)D) concentrations.¹¹⁵ In their natural state, dogs and cats would have satisfied their vitamin D requirements from ingesting the fat, liver, and blood of their quarry, but pet dogs and cats now rely on dietary supplements.⁹² Most herbivores are able to produce vitamin D₃ in response to ultraviolet irradiation of the skin, as indicated by the higher concentrations of serum vitamin D₃ in shorn sheep than in unshorn sheep.^{29,81} Llamas and alpacas have been found to be highly susceptible to vitamin D deficiency. These camelids have evolved with a thick hair coat and pigmentation to protect them against the intense solar radiation present in their natural environment in the high Andes.^{25,82,209} When transferred to lower altitudes or higher latitudes where solar radiation is much lower, serum vitamin D concentrations in llamas and alpacas decline to low levels, especially during winter.^{182,211}

Once vitamin D₃ is formed in the skin, it preferentially binds to vitamin D-binding protein in the capillaries of the dermis, and it is either stored in fat or transported to the liver.⁸⁷ Whether obtained from sun exposure or diet, vitamins D₂ and D₃ are biologically inactive and must undergo two hydroxylation reactions to be activated.⁴⁹ Figure 1 shows the steps involved in the conversion of vitamin D to its active form: 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃). The 25-hydroxylation occurs mainly in the liver, whereas the second 1α-hydroxylation takes place in the kidneys. Vitamin D becomes biologically active only after the second hydroxylation is complete.

Hepatic 25-hydroxylation. A number of hepatic cytochrome P450s have been postulated as carrying out 25-hydroxylation of vitamin D, including CYP27A1, CYP3A4, CYP2R1 and CYP2J3,¹⁶² and this step in vitamin D metabolism is largely unregulated. Because of its strong association with vitamin D-binding protein, 25(OH)D₃ is stable and is the main form of vitamin D in circulation.¹⁰⁰ The concentration of 25(OH)D in serum is proportional to dietary intake and is therefore a useful measure of dietary consumption and/or skin production.⁸⁷

Renal 1α-hydroxylation. The next step in the process of vitamin D activation depends on the plasma ionized calcium concentration. If plasma ionized calcium concentration is low, renal 1α-

hydroxylation of 25(OH)D occurs to produce the active form of vitamin D (1,25(OH)₂D₃), but if the calcium concentration is adequate, 25(OH)D undergoes 24-hydroxylation to an inactive metabolite.¹⁰⁰ The renal 1α-hydroxylase (CYP27B1) is also regulated by parathyroid hormone (PTH), calcitonin, and feedback inhibition by 1,25(OH)₂D₃. When plasma ionized calcium is low, PTH may directly stimulate the 1α-hydroxylase gene promoter or indirectly stimulate renal 1α-hydroxylase mRNA production and activity via cAMP pathways.^{21,147,171} However, when plasma ionized calcium concentrations are normal, calcitonin is thought to upregulate renal 1α-hydroxylase production of 1,25(OH)₂D₃.^{147,226} The feedback inhibition of 1α-hydroxylase by 1,25(OH)₂D₃ is mostly due to inhibition of PTH and the cAMP pathways.²¹

Plasma phosphate concentration is also involved in the control of 1,25(OH)₂D₃ production. Low plasma phosphate concentration induces renal 1α-hydroxylase activity independent of either PTH or calcium concentrations.^{5,68} High plasma phosphate concentration inhibits 1,25(OH)₂D₃ formation through the activity of the phosphatonins, fibroblast growth factor 23, and secreted frizzled-related protein 4.¹²

Catabolism Pathways

The two main pathways responsible for the catabolism of active vitamin D are catalyzed by CYP24.⁹ The first involves C-24 oxidation to calcitric acid,¹⁰⁰ whereas the second involves conversion of 1,25(OH)₂D₃ to 1,25(OH)₂D₃-26,23-lactone via a 23-hydroxylation.¹⁶² The CYP24 gene contains two vitamin D-responsive elements (VDREs) in its promoter. These elements allow 1,25(OH)₂D₃ to upregulate CYP24 expression via the vitamin D receptor (VDR) and stimulate its own catabolism.^{43,227} PTH and plasma phosphate concentrations are also involved in the control of the catabolic pathways.^{192,193,228} When serum ionized calcium concentrations are normal and PTH is suppressed, CYP24 activity and expression increase such that 25(OH)D is converted to the much-less-potent 24,25-dihydroxyvitamin D₃, and 1,25(OH)₂D₃ is catabolized.^{193,227,228} However, low plasma phosphate concentration decreases CYP24 expression and activity, thus reducing 1,25(OH)₂D₃ catabolism.^{192,221}

The Vitamin D Receptor

The VDR is a member of the family of type II nuclear receptors for steroid hormones. These receptors require heterodimerization with retinoid X receptors (RXRs) to increase their affinity for the ligand—in this case, 1,25(OH)₂D₃.^{7,163} The VDR protein contains four main domains: ligand binding, heterodimerization with the RXR, binding of VDREs, and enlistment of coregulators.⁴⁹ In the nucleus, VDR-RXR-1,25(OH)₂D₃ binds to specific sequences called VDREs present in the promoter area of the target gene.^{78,96} Nuclear coactivators and transcription factors, positive and negative, interact with the VDR-RXR-1,25(OH)₂D₃ to augment or repress 1,25(OH)₂D₃ gene transcription activation.^{49,164} For further description of the




Figure 1. Vitamin D synthesis, activation, and breakdown: Exposure of 7-dehydrocholesterol in the skin to ultraviolet irradiation leads to thermal isomerization to vitamin D₃, which is transported by vitamin D-binding protein to the liver. Vitamin D₃ 25-hydroxylation occurs in the

molecular signaling of $1,25(\text{OH})_2\text{D}_3$, we refer to the reviews by Dusso et al.⁴⁹ and Haussler et al.⁷⁸

Functions of Vitamin D

The main target organs for vitamin D are the intestine, bone, kidney, and parathyroid glands.⁴⁹ With PTH, the primary function of vitamin D is to maintain plasma ionized calcium and phosphate concentrations within narrow physiological limits.

Intestine. In the intestine, $1,25(\text{OH})_2\text{D}_3$ promotes active uptake and transcellular transport of calcium. The epithelial calcium channel, transient receptor potential vanilloid 6 (TRPV6), transports calcium into the cell where it binds to calbindin D and is transported across the cell.¹⁹⁰ A Ca^{2+} -ATPase (PMCA1b) and $\text{Na}^+/\text{Ca}^{2+}$ exchanger (NCX1) then discharges calcium into the bloodstream.¹⁸ Paracellular transport of calcium down an electrochemical gradient also occurs.²⁰⁷ TRPV6 and calbindin are upregulated by $1,25(\text{OH})_2\text{D}_3$, thereby increasing intestinal calcium absorption,^{86,143} whereas high blood calcium concentrations provide negative feedback on the numbers of TRPV6 channels, thereby reducing intestinal calcium absorption.⁸⁶ TRPV6 and calbindin may also be induced, independent of vitamin D and blood calcium concentrations, by high dietary and intestinal calcium concentrations.²⁰⁷

Active phosphate absorption in the intestine may also be increased by $1,25(\text{OH})_2\text{D}_3$, which leads to increased expression of the Na-P_i transporter and altered intestinal cell membrane lipid composition.^{113,222}

Bone remodeling. In the skeleton, $1,25(\text{OH})_2\text{D}_3$, in association with PTH, promotes mobilization of calcium from bone stores to maintain ionized blood calcium concentration within a narrow range.⁸⁹ This is thought to be achieved by stimulation of RANKL (receptor activator for NF- κ B ligand) and increased osteoclastogenesis.³ RANKL, a surface ligand on osteoblasts, can bind either to osteoclasts via RANK (receptor activator for NF- κ B) or to a decoy receptor called osteoprotegerin (OPG).¹⁸⁹ When RANKL binds to RANK, it induces differentiation and maturation of osteoclast progenitor cells to osteoclasts.¹⁹¹ RANKL is stimulated by $1,25(\text{OH})_2\text{D}_3$ via VDREs on the RANKL promoter, thereby inducing osteoclastogenesis, resorption of bone, and mobilization of calcium.¹⁰⁸ OPG production is inhibited by $1,25(\text{OH})_2\text{D}_3$.¹¹⁰ If RANKL binds to OPG, osteoclastogenesis and bone resorption is inhibited.¹⁹

Bone growth and mineralization. It is uncertain whether vitamin D affects bone growth and mineralization directly or indirectly by altering calcium and phosphate concentrations in the extracellular fluid via intestinal uptake of calcium.¹⁸⁹ If ionized calcium and phosphate concentrations are within the

physiological range, $1,25(\text{OH})_2\text{D}_3/\text{VDR}$ is apparently not essential for mineralization of osteoid.¹⁵² However, osteoblasts and chondrocytes express both 25-hydroxyvitamin D- 1α -hydroxylase and VDR,¹⁸⁷ and both calcium and $1,25(\text{OH})_2\text{D}_3$, independent of the VDR, are thought to be required for normal growth plate development.^{73,152} Juvenile mice with inactivation of the VDR in chondrocytes have impaired vascular invasion and decreased osteoclast numbers, leading to a transient increase in the density of the primary spongiosa.^{136,187} Similarly, mice with chondrocyte-specific inactivation of 1α -hydroxylase also have impaired vascular invasion and increased neonatal bone volume, in addition to increased width of the hypertrophic zone of the growth plate.¹⁴⁹ These mouse models suggest an intracrine role for $1,25(\text{OH})_2\text{D}_3$ in endochondral ossification, over and above the endocrine role of keeping serum calcium and phosphate within normal limits.

Parathyroid glands. The VDR and $1,25(\text{OH})_2\text{D}_3$ are not essential for controlling PTH production, but they do work in conjunction with calcium.^{49,73} Deficiency of vitamin D results in hypocalcemia, which leads to parathyroid hyperplasia and secondary hyperparathyroidism.¹⁴⁴ Conversely, $1,25(\text{OH})_2\text{D}_3$ suppresses parathyroid cell growth by decreasing growth factors (transforming growth factor-epidermal growth factor receptor growth loop) and increasing known inhibitors of cell growth (cyclin-dependent kinase inhibitors p21 and p27).⁵⁰ This is the physiological basis behind the use of active vitamin D in treating people for secondary hyperparathyroidism in end-stage chronic renal disease.²²⁰ In addition, active vitamin D has been shown to upregulate calcium-sensing receptor expression by binding to VDREs on the calcium-sensing receptor gene promoter, leading to increased sensitivity of the parathyroid gland to plasma ionized calcium and decreased PTH secretion.^{24,28}

Kidney. The main role of $1,25(\text{OH})_2\text{D}_3$ in the kidney is to control its own production by inhibition of renal 1α -hydroxylase and stimulation of CYP24 (24-hydroxylase).⁴⁹ Whether $1,25(\text{OH})_2\text{D}_3$ has any direct effect on renal filtration of calcium and phosphate is controversial, given that its effects are clouded by its actions on PTH and intestinal calcium and phosphate absorption.⁴⁹ Calcium transport across renal epithelial cells is similar to that which occurs across intestinal epithelial cells. The epithelial calcium channel (TRPV5) is present on the apical cell membrane of cells in distal convoluted tubules and collecting ducts of the kidney and transports calcium into the cell.¹⁹⁰ Calbindin- $\text{D}_{28\text{K}}$ transports calcium across the renal tubular cell, and the calcium transporters PMCA1b and NCX1 on the basolateral cell membrane release calcium into the bloodstream.¹⁷ PTH, $1,25(\text{OH})_2\text{D}_3$, and estrogen may all independently induce upregulation of TRPV5, calbindin- $\text{D}_{28\text{K}}$,

Figure 1. (continued). liver by cytochrome P450, which is followed by transport to the kidney and 1α -hydroxylation in the proximal convoluted tubules to produce $1,25$ -dihydroxyvitamin D_3 , the active form of vitamin D. Also included are the breakdown pathways catalyzed by CYP24 cytochromes. Isomerization of 7-dehydrocholesterol also produces tachysterol and lumisterol, which are biologically inert and are sloughed off in keratinocytes during normal skin turnover.

PMCA1b, and NCX1 gene expression.^{17,84,85,206} PTH-dependent calcium transport in distal convoluted tubules may also be accelerated by $1,25(\text{OH})_2\text{D}_3$.⁶⁶ Renal tubular reabsorption of phosphate is increased by $1,25(\text{OH})_2\text{D}_3$ when PTH is present, but this is unlikely to be a direct effect on the kidney.⁴⁹

Other Effects

Vitamin D has also been shown to have other endocrine and autocrine/paracrine roles in multiple cell types and organs. Vitamin D may protect against cancer and possibly even treat cancer by suppression of cell growth.^{69,111,229} In one study, serum vitamin D concentration and the incidence of some cancers were shown to be inversely related, although many confounding factors were present.³⁹ Vitamin D may also have a role in the immune system; it may be involved in prevention of cardiovascular disease, hypertension, and diabetes mellitus; and it may aid in treatment of rheumatoid arthritis, inflammatory bowel disease, psoriasis, and multiple sclerosis.^{15,100,146,229}

Toxicity

In spite of its many beneficial effects, an excess of vitamin D is toxic, causing widespread soft tissue mineralization secondary to persistent hypercalcemia and hyperphosphatemia.¹⁴⁸ Affected animals show severe gastrointestinal signs, hypertension, heart rhythm abnormalities, neurological signs (eg, seizures), and, eventually, death.^{75,148,154} This underlies the use of cholecalciferol as a pesticide in some countries. The pathogenesis of cholecalciferol toxicity is not completely understood, because serum $1,25(\text{OH})_2\text{D}_3$ concentrations are usually normal whereas serum $25(\text{OH})\text{D}$ concentrations are 10 to 20 times greater than the normal range.¹⁷⁴ It is possible that high concentrations of $25(\text{OH})\text{D}$ activate the VDR and stimulate gene transcription of vitamin D-responsive genes or that the high concentration of all vitamin D metabolites overwhelms the vitamin D-binding protein, leading to release of free $1,25(\text{OH})_2\text{D}_3$, which then enters the cell and stimulates gene transcription.⁹⁹

Pathology of Rickets

The characteristics of rickets are similar in all species. Lesions are typically most severe in the fastest-growing bones, including the radius, the tibia, and the metacarpals and metatarsals.^{60,150} On radiographic and postmortem examination, widening of the physeal growth plate is the most archetypal change.^{60,109,156} Other abnormalities seen radiographically may include metaphyseal flaring, thinning of the cortex, poor mineralization of the skeleton, and pathological fractures.^{48,109,139,156} In addition, postmortem examination may reveal irregular thickening of the physeal cartilage, erosion of articular cartilage due to collapse of subchondral bone, and spontaneous fractures.^{60,150,197} Enlargement of costochondral junctions, the so-called rachitic rosary, is also a classic lesion of rickets that may be seen on radiographic or postmortem examination.^{60,139}

Impaired provisional calcification of cartilage at sites of endochondral ossification leads to the accumulation of hypertrophic chondrocytes, resulting in thickened and irregular growth plates with islands and tongues of chondrocytes extending into the metaphyses.^{60,197,200} Similar changes occur beneath articular epiphyseal cartilage complexes in the expanding epiphyses of young animals.²⁰⁰ Other microscopic changes may include thick osteoid seams lining trabeculae and disorganization or absence of the primary spongiosa.^{150,160,200} One of the early pioneers of research into rickets, Sir Arnold Theiler, regarded the pathognomonic change as “the presence of osteoid tissue in quantities surpassing normal physiological limits.”^{198(p 1145)} Hemorrhage and signs of trauma may be seen in the metaphysis and primary spongiosa because of damage to weakened trabeculae of poorly mineralized bone.^{16,200,201}

Rickets in Humans

Nutritional Causes

In the developed world, nutritional rickets has been reemerging as a disease problem; in Third World countries, it never went away and is thought to be one of the five most common diseases of children.^{2,77} Medical writings from the first and second centuries described the classical bone deformities associated with rickets, and in the mid-17th century, Daniel Whistler and Francis Glisson wrote the first detailed medical reports.^{158,165} It was not until the industrial revolution, however, that rickets became an epidemic.^{158,165} In 1909, histological evidence of rickets was an incidental finding in 96% of children who died at less than 18 months of age.¹⁶⁵ At that time rickets was associated with heavy air pollution, urbanization, overcrowding, and inadequate diet.¹⁵⁸ Experimental work in the early 20th century confirmed the efficacy of the traditional remedy for treating rickets, cod liver oil, and eventually, vitamin D was named in 1922 as the agent responsible for preventing the disease.^{158,165}

Rickets in humans is seen most commonly either during infancy or at puberty, corresponding to periods of maximal growth.²¹⁶ The common clinical signs in humans include craniotabes, skeletal deformities (eg, bowed or knock-kneed legs), rachitic rosary, delayed eruption of teeth, and enamel hypoplasia.^{161,216} Low to normal calcium and phosphate concentrations, high PTH concentration, high alkaline phosphatase activity, low $25(\text{OH})\text{D}_3$, and normal to high $1,25(\text{OH})_2\text{D}_3$ concentrations (if adequate vitamin D is present) are typically seen in the serum of children with nutritional rickets.^{109,161,216}

In developed countries, nutritional rickets is most often associated with exclusive breast-feeding.^{34,157,158,204} Although vitamin D readily passes into it, breast milk is low in vitamin D (reported values of 4 to 40 IU/liter)^{117,167} and does not supply an infant's daily requirements (200 to 400 IU/liter).^{117,214} The vitamin D metabolites, $25(\text{OH})\text{D}_3$ and $1,25(\text{OH})_2\text{D}_3$, pass poorly into breast milk. Most breast-fed infants acquire vitamin D through sunlight exposure; however, this is affected by such factors as skin pigmentation,⁸⁷ the amount of skin exposed to sunlight,¹³⁸ air pollution,¹ latitude,^{159,213} cloud cover,²¹⁴ and

sunscreen usage.¹³⁷ In a review of reports on nutritional rickets from 1986 to 2003 in the United States, 83% of children with rickets were African American or other dark-skinned races, and 96% were breast-fed.²¹⁴

In the United Kingdom and Northern Europe, rickets is most common in infants and children of either Asian or Afro-Caribbean origin.^{76,91,93,155} In these communities, risk factors include latitude, vegetarianism, consumption of chapattis or flatbread, traditional clothing, and social customs with limited exposure to sunlight.^{8,155,158} Vegetarian diets and flatbreads typically contain high concentrations of phytates and dietary fiber, which may lead to vitamin D deficiency when combined with low calcium intake and limited exposure to the sun.^{8,158}

The elderly and housebound are also at risk, and although clinical osteomalacia is not common in this age group, its 25(OH)D₃ concentrations are frequently low.^{22,140,215} Elderly people generally spend more time indoors, and aged human skin has reduced ability to produce vitamin D following exposure to ultraviolet light.¹²⁸

Food allergies are considered a possible risk factor for nutritional rickets.^{63,95} Allergies to hens' eggs, cows' milk, and peanuts are the most common and may lead to parents' giving their children diets that are nutritionally unbalanced.^{63,151} Soy milk is a common substitute for cows' milk in allergic individuals, but it is low in calcium, phosphorus, magnesium, and vitamin D.⁹⁵ Such a diet is unsuitable as a complete food for infants and may lead to the development of rickets.^{63,95} Gastrointestinal disease or cholestatic liver disease may also lead to the development of rickets and osteomalacia because of malabsorption, impaired 25-hydroxylase activity, changes in enterohepatic circulation, intestinal unresponsiveness to vitamin D, and excessive fecal loss of vitamin D.^{134,181}

Genetic Causes

A number of heritable causes of rickets and osteomalacia have been identified and are most commonly due to a defect in either vitamin D metabolism or renal tubular function.²¹⁸

Heritable diseases associated with renal phosphate wasting include X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, and hereditary hypophosphatemic rickets with hypercalciuria.^{58,168} These diseases, as well as tumor-induced osteomalacia, are characterized by hypophosphatemia, renal inorganic phosphate wasting, rickets, and inappropriately low to normal 1,25(OH)₂D₃ concentrations.^{14,168,218}

XLH has an X-linked dominant mode of inheritance, and with one in 20,000 people affected, it is the most common form of hereditary rickets in humans.¹⁴ In addition to the microscopic changes of rickets, "halos" of unmineralized osteoid surround individual osteocytes (hypomineralized periosteocytic lesions), a lesion considered pathognomonic for this disease.²¹⁸ The genetic mutation that causes XLH has been isolated to the *PHEX* gene on chromosome 22 in the human genome.⁴⁷ *PHEX* stands for "phosphate-regulating gene with homologies to endopeptidases on the X-chromosome," and it

produces a protein that has homology with membrane-bound metalloproteinases.^{47,172} No single predominant mutation in *PHEX* causes XLH, and in mutational analysis of patients with XLH, 18 mutations in *PHEX* were found.⁹⁴ The mechanism by which *PHEX* mutations cause XLH has yet to be elucidated.⁹⁴ One hypothesis is that a circulating factor that is degraded or processed by *PHEX* influences phosphate reabsorption in the kidney. Candidates for the circulating factor are known as phosphatonins and include fibroblast growth factor 23 (FGF23), matrix extracellular phosphoglycoprotein, and secreted frizzled-related protein 4.^{12,14,168} The mechanism of vitamin D dysfunction is unknown, although phosphatonins like FGF23 do inhibit 1,25(OH)₂D₃ production.¹⁷⁶ A similar mechanism is behind tumor-induced osteomalacia in humans, where the production of the same phosphatonins by mesenchymal tumors (mixed connective tissue type) leads to renal phosphate wasting and osteomalacia.^{12,62}

Autosomal dominant hypophosphatemic rickets is less common than XLH. Mutations in the gene for FGF23 on chromosome 12 are believed to be the cause of autosomal dominant hypophosphatemic rickets.¹⁹⁶ Such mutations induce loss of a cleavage site on FGF23, leading to an increase in its activity and consequent phosphaturia, hypophosphatemia, and rickets.^{6,123,178}

Three families have been identified with autosomal recessive hypophosphatemic rickets.¹⁶⁶ The patients had renal phosphate wasting and elevated FGF23 concentrations.¹²⁶ Mutations were found in the gene for dentin matrix protein 1 (DMP1), a noncollagenous bone protein.^{58,126}

Hereditary hypophosphatemic rickets with hypercalciuria is characterized by autosomal recessive inheritance and was first described in a Bedouin family.²⁰⁵ In contrast to other hypophosphatemias, 1,25(OH)₂D₃ is elevated, possibly explaining the hypercalciuria.^{168,205} The disease occurs as a result of a single nucleotide deletion in the gene coding for the NaP_i-IIc protein (a renal Na-P_i cotransporter), truncating the protein in patients homozygous for the deletion.¹¹

Vitamin D-dependent rickets type I (VDDR I) or pseudovitamin D-deficiency rickets is an autosomal recessive disorder caused by a failure to convert 25(OH)D₃ to 1,25(OH)₂D₃,⁶⁵ most likely because of a defect in renal 25-hydroxyvitamin D₃-1 α -hydroxylase.^{65,106} Affected individuals have normal serum 25(OH)D₃ concentrations and low 1,25(OH)₂D₃ concentrations.²¹⁸ The defect in VDDR I involves the *CYP27B1* gene (encoding 25-hydroxyvitamin D₃-1 α -hydroxylase) on chromosome 12q13.3, and a number of mutations in the gene have been detected in affected individuals.^{67,107,212,225}

Hereditary vitamin D-resistant rickets (HVDRR), or vitamin D-dependent rickets type II, was first described in 1978, with patients showing hypocalcemia, secondary hyperparathyroidism, and high serum 1,25(OH)₂D₃ concentrations.^{23,135} Patients were normal at birth owing to transplacental calcium flux between the mother and fetus, but skeletal changes and hypocalcemia were evident from 2 to 8 months of age.¹²² Approximately 75% of affected individuals are born to consanguineous parents.¹³³ Partial to total alopecia—including eyebrows and, in some cases, eyelashes—is present in 70 to

Table 1. Selected Models of Metabolic Bone Disease in Mice and Rats^a

Mouse Model	
Hyp ⁵²	
Human disease equivalent	X-linked hypophosphatemic rickets
Abnormalities	Hypophosphatemia, rickets, dwarfism, inappropriately normal plasma (1,25(OH) ₂ D ₃), high fractional excretion of phosphate
Gy ¹²⁷	
Human disease equivalent	X-linked hypophosphatemic rickets
Abnormalities	Hypophosphatemia, rickets, circling, inner ear abnormalities, increased plasma (1,25(OH) ₂ D ₃), increased renal phosphate loss
FGF23 knockout ¹⁷⁷	
Abnormalities	Growth retardation, shortened life span, hyperphosphatemia, increased renal phosphate reabsorption, increased plasma (1,25(OH) ₂ D ₃), focal osteomalacia
1 α -hydroxylase knockout ^{38,153}	
Human disease equivalent	Vitamin D–dependent rickets type I
Abnormalities	Rickets, growth retardation, hypocalcemia, low plasma (1,25(OH) ₂ D ₃), high plasma (25(OH)D ₃), hyperparathyroidism
VDR null or VDR ^{−/−26,121}	
Human disease equivalent	Hereditary vitamin D–resistant rickets
Abnormalities	Alopecia, rickets, hypocalcemia, hypophosphatemia, hyperparathyroidism
VDR/RXR _{γ} knockout ²²³	
Abnormalities	Growth retardation, rickets, more severe bone abnormalities than VDR ^{−/−} , hypocalcemia, alopecia
Cyp24a1 (24-hydroxylase) knockout ¹⁸⁸	
Abnormalities	Death of 50% of progeny at less than 3 weeks because of high plasma (1,25(OH) ₂ D ₃) and hypercalcemia, accumulation of unmineralized osteoid at sites of intramembranous ossification
24-hydroxylase transgenic rats ¹⁰³	
Abnormalities	Constitutive expression of 24-hydroxylase, albuminuria, hyperlipidemia, atherosclerosis, urinary loss of vitamin D–binding protein and 25(OH)D, decreased plasma (24,25(OH) ₂ D ₃)
DMP1 knockout	
Human disease equivalent	Autosomal recessive hypophosphatemic rickets
Abnormalities	Rickets, osteomalacia, elevated fibroblast growth factor 23, hypocalcemia, hypophosphatemia, inappropriately normal plasma (1,25(OH) ₂ D ₃), mineralization defects, defective osteoblast to osteocyte differentiation and maturation
Vitamin D–binding protein knockout ¹⁷³	
Abnormalities	On a vitamin D–replete diet, mice are normal; on a vitamin D–deficient diet, mice develop secondary hyperparathyroidism and rickets; and on a diet excessive in vitamin D, mice are resistant to the development of hypercalcemia.
Ca ²⁺ -sensing receptor knockout ⁷⁰	
Abnormalities	Rickets, dwarfism, hypercalcemia, hypophosphatemia, hyperparathyroidism

^a VDR, vitamin D receptor; RXR, retinoid X receptor.

80% of affected individuals.¹³³ The disease occurs because of either hormone-binding defects or DNA-binding defects of the VDR.¹³³ A third group of defects was originally thought to comprise defective receptor translocation to the nucleus,^{80,217} but recent work has shown that this defect is the result of constitutive overexpression of heterogeneous nuclear riboprotein and its competition with the VDR-RXR complex for binding to the VDRE.^{31,32}

Animal Models of Rickets

A number of mouse models have been discovered or created to study human skeletal diseases. Table 1 summarizes some of

these, with a selection of other models that have been created to study the function of different hormones and proteins involved in skeletal homeostasis.

Mouse Models

Two naturally occurring models of hypophosphatemic rickets due to renal phosphate wasting have been described in mice: the Gy mouse and Hyp mouse.^{52,127} Both are characterized by hypophosphatemia, rickets, normal to high 1,25(OH)₂D₃, and increased renal phosphate loss. The Gy mouse also has inner ear abnormalities that lead to circling.¹²⁷ The phenotype

observed in the Hyp mouse is the result of excessive FGF23 concentrations due to inactivating mutations in *PHEX*.¹²⁴

Four strains of *VDR* null mice have been developed. The Tokyo strain has exon 2 of the *VDR* gene removed (exon 2 encodes the first of two zinc fingers involved in DNA binding),²⁶ and the Boston strain has exon 3 removed (which encodes the second zinc finger).¹²¹ Two other strains also have a missing first zinc finger.^{54,208} The disease in all strains is phenotypically similar to HVDRR in humans.²⁶ Affected mice are normal at birth but become hypocalcemic and hypophosphatemic and develop hyperparathyroidism by 21 days of age.¹²¹ The *VDR*-null mice develop rickets and osteomalacia by day 35.¹²¹ *VDR*-null mice also develop progressive alopecia, commencing at around 4 weeks of age and becoming complete by 100 days.^{41,121} *VDR*-null mice fed a diet high in calcium (2.00%), phosphorus (1.25%), and lactose from day 18, before the development of serum biochemical changes, do not develop rickets and osteomalacia but still become alopecic,¹²⁰ which suggests that the *VDR* is not required for the prevention of hyperparathyroidism or for normal skeletal homeostasis.⁴¹

The *DMP1*-knockout mouse is a model for autosomal recessive hypophosphatemic rickets. These mice have renal phosphate wasting, elevated FGF23, and inappropriately normal serum 1,25(OH)₂D₃ concentrations.^{58,126} *DMP1* is thought to promote mineralization of osteoid, and it may be required for differentiation of osteoblasts into osteocytes.⁵⁸ *DMP1* also leads to upregulation of FGF23 by an unknown pathway.¹²⁵

Nonhuman Primates

New World monkeys may also be used as a model for HVDRR. The marmoset (*Callithrix jacchus*) in particular requires a diet high in vitamin D₃ for normal growth. Concentrations of 1,25(OH)₂D₃ in marmosets are 4 to 10 times higher than those in rhesus monkeys or humans, suggesting relative end-organ resistance to 1,25(OH)₂D₃.^{179,224} Recent evidence has suggested that this resistance to 1,25(OH)₂D₃ in marmosets is not due to the *VDR* but instead to overexpression of a *VDR*-independent VDRE-binding protein, which interferes with vitamin D-regulated transactivation.^{33,35} Marmosets also have high circulating glucocorticoid concentrations and are resistant to high levels of glucocorticoids, suggesting that the species may be resistant to a variety of steroid hormones, not just 1,25(OH)₂D₃.¹⁷⁹

Sheep and Goats

Rickets is uncommon in sheep, and until recently, all reported cases had been nutritional in origin. Fitch and Ewer both performed extensive investigations into rickets in sheep in the 1940s and 1950s.^{57,59-61} In New Zealand, rickets occurred most commonly in the South Island in winter, in association with the feeding of greenfeed oats to growing lambs approaching 1 year of age. Although calcium and phosphorus levels were adequate,⁵⁷ the crops contained high concentrations of carotene, which has been shown to antagonize the action of vitamin D

on the intestine and bone.^{74,97,169} Although rickets is most common in sheep fed cereal crops, the disease may occur in lambs grazing pasture, Italian ryegrass, choumoellier, and turnips.⁵⁷ Such feeds also have high concentrations of carotenes; however, cereal crops may be more rachitogenic because of the higher availability of carotene.⁷⁴

Naturally occurring rickets is also uncommon in sheep in the United Kingdom,^{16,55,142,150} but outbreaks associated with high latitude, low sunshine hours, and poor-quality pasture low in phosphorus have occurred in Scotland.^{16,150} In Ireland, rickets has occurred in sheep fed oats in winter months and, in northern England, in sheep grazing lush ryegrass swards over winter, most likely because of the rachitogenic effect of carotenes.^{37,142}

Clinical signs of rickets in sheep include stiff gait, lameness, enlarged joints (particularly, the radiocarpal), bowed or bent legs, and loss of condition or poor weight gain.^{16,37,48,56,60,150,210} Rickets is most commonly seen in recently weaned animals because of the rapid growth at this age and their dependence on pasture or crops.^{16,150}

Sheep have a seasonal trough in serum 25(OH)D concentrations in late winter, owing to fleece cover and reduced exposure to ultraviolet light.¹⁸⁴ This is exacerbated by the demands of pregnancy.^{184,185} The serum vitamin D concentration of lambs has been shown to be closely related to the vitamin D concentration of the dam.^{184,185} Lambs at 3 to 4 weeks predominantly rely on milk, which may have low vitamin D concentrations if the vitamin D status of the dam is inadequate.²¹⁰

An unusual outbreak of rickets was described in lambs of 3 to 4 weeks of age in Oregon.²¹⁰ Because ewes' milk may be low in vitamin D, vitamin D deficiency was considered the most likely cause of the outbreak. Although rickets was not confirmed histologically, the clinical signs, low 25(OH)D concentrations, and positive response to treatment with cholecalciferol suggest that vitamin D deficiency was the likely cause of the bone deformities.²¹⁰

Skeletal lesions resembling rickets were reported in goat kids fed artificial milk intended for calves on a large commercial farm in the Netherlands.⁴² Physal changes were not present microscopically, but the authors described broad osteoid seams in the primary and secondary spongiosa. The synthetic calf milk had a calcium:phosphorus ratio of 0.83:1.00, which was considered low. Given the absence of growth plate changes in this case and the adequate phosphorus concentration of the diet, a diagnosis of nutritional secondary hyperparathyroidism should be considered. Formation of poorly mineralized woven bone is a feature of fibrous osteodystrophy and may resemble osteoid seams in some circumstances.²⁰⁰

Recently, a form of rickets with autosomal recessive inheritance has been described in Corriedale sheep from New Zealand.^{44,46,202} The clinical signs resembled rickets in other species and included decreased growth rate, thoracic lordosis, and angular limb deformities. Lesions at necropsy included segmental thickening of the physes, collapse of subchondral bone of the humeral head (Fig. 2), thickened cortices, and enthesophytes around distal limb joints.^{46,202}



Figure 2. Proximal humerus; 1-year-old Corriedale sheep with inherited rickets, showing flattening of the humeral head and separation of articular cartilage from collapsed subchondral bone (white arrow). Also note the segmental thickening of the physis (black arrow), thickened metaphyseal trabeculae, and thickened cortices.

Microscopically, there was persistence of hypertrophic chondrocytes at sites of endochondral ossification, inappropriate and excessive osteoclastic resorption, microfractures, and wide unmineralized osteoid seams lining trabeculae (Fig. 3) and filling secondary osteons.⁴⁶ Although initial biochemistry results suggest a defect in the VDR analogous to HVDRR of humans,²⁰² subsequent *in vitro* studies on cultured skin fibroblasts showed that the VDR was normal. The genetic defect in Corriedale sheep may be different from those currently described in humans and animals to date.

Cattle

There are few published reports of naturally occurring rickets in cattle, and no inherited forms have been described. The




Figure 3. Rib; 2-year-old Corriedale sheep with inherited rickets, showing unmineralized osteoid seams lining trabeculae (black arrow) and cortical resorption cavities. Goldner's trichrome method. Bar = 100 μm .

earliest published investigations on rickets and osteomalacia in cattle were conducted by Sir Arnold Theiler and colleagues in South Africa.^{198,199} In their studies, phosphorus deficiency was shown to be the basis of a syndrome characterized by osteophagia, stiff gait, lameness, swollen joints, and sometimes spontaneous fracture.¹⁹⁸ Vitamin D deficiency was not considered a contributing factor, because of the abundant sunshine available in South Africa.¹⁹⁸ A similar syndrome reported in the Northern Territory of Australia was referred to as *stiffs*, *creeps*, or *peg-leg*. The disease occurred during periods of drought; osteophagia was a feature; and phosphorus deficiency was considered the cause.¹⁷⁰

Cattle are considered more susceptible than sheep to phosphorus deficiency.²⁰⁰ In a 10-year trial investigating the effect of phosphorus deficiency in cattle, the main skeletal changes were osteoporosis and osteomalacia.¹⁸⁰ When dietary phosphorus was less than 6 g per day, loss of body condition occurred, as did lameness, abnormal stance, spontaneous fractures, reproductive failure, and hypophosphatemia. Clinical recovery occurred within 6 months once the dietary phosphorus deficiency was corrected.¹⁸⁰

One published report involved 4 yearling bullocks housed inside and fed oats, sugar beet pulp, barley, hay, and raw potatoes.¹⁸⁶ The cows on the farm also showed signs of fluorosis, which may have contributed to the development of rickets in the yearlings. Fluoride stimulates bone formation, increasing skeletal demand for calcium and perhaps exacerbating vitamin D deficiency.^{105,112} Rickets has also been reported in children in areas of India with water containing high fluoride levels.¹⁰⁵

A similar skeletal disease was reported in Sweden, in fattening bulls kept indoors and fed a concentrated diet with high levels of phosphorus.¹⁰¹ The clinical, biochemical,




Figure 4. Costochondral junction; 1-year-old steer with tongues of cartilage (black arrows) extending into the metaphysis of a costochondral junction.

and radiological changes were consistent with rickets, and histologically there were features of fibrous osteodystrophy and rickets. This combination would be expected in vitamin D deficiency, which leads to low calcium and subsequent secondary hyperparathyroidism.

In New Zealand, rickets was reported in yearling Angus steers fed a swede crop over winter. Affected cattle had poor growth rate and lameness that became severe when moved from the crop onto hill country grazing land.²⁰¹ Steers developed vertebral fractures leading to posterior paralysis, and rickets (Fig. 4) was confirmed histologically.²⁰¹ The phosphorus concentration of the crop, when combined with the low dry matter content, was inadequate to supply daily phosphorus requirements.²⁰¹

Llamas and Alpacas

Since being transported from the Andes to other parts of the world, llamas and alpacas have been found to be highly susceptible to rickets. A peak in the incidence of rickets in crias occurs from January to March in the Northern Hemisphere.²¹¹ In this study, crias born in autumn/winter had lower vitamin D concentrations and were more likely to develop rickets than were those born in summer.²¹¹ The reason may be that these animals receive less vitamin D via the placenta or colostrum because of the low level of solar radiation at that time of year,¹⁸² and a young cria's diet consists substantially of milk, which is low in vitamin D.²¹¹ Interestingly, alpacas appear to be more susceptible to rickets than sheep. In an outbreak in New Zealand,




Figure 5. Distal femur; 5-month-old alpaca with rickets, showing segmental physal thickening (black arrows).

alpacas became hypophosphatemic and developed rickets during winter months (Fig. 5), whereas lambs grazing the same pasture with the alpacas showed no signs of phosphorus deficiency.⁸²

Horses

Rickets is rare in horses and appears to occur less frequently than in other domestic species.⁵³ Experimentally, Shetland ponies deprived of sunlight and dietary vitamin D showed irregularly widened physes on radiographs, consistent with rickets.⁵³ Compared to other animal species, horses have higher serum calcium concentrations and lower serum 25(OH)D and 1,25(OH)₂D₃ concentrations.^{20,131,183} In fact, the vitamin D metabolite concentrations—25(OH)D and 1,25(OH)₂D₃—in horses are lower than those at which rickets occurs in other animals,²⁰ suggesting a species variation and perhaps indicating different mechanisms for calcium and phosphate metabolism in horses. This is possibly reflected in the fact that a large proportion of calcium in the horse is excreted via the kidney into the urine, as evidenced by the large amount of calcium carbonate crystal present in the urine of horses.⁵¹

Pigs

Piglets grow rapidly and are weaned early, making them susceptible to rickets if their diet contains inadequate vitamin D.²⁰⁰ In intensive pig farming where animals are housed in a controlled environment, vitamin D requirements of the pig are usually supplied by the diet.²⁰⁰

An outbreak of rickets affecting 82 pigs was described on a small fattening unit in Scotland.¹⁵⁶ The pigs were emaciated and had difficulty rising; they also had bowed forelegs, joint swellings, and pain on moving. Folding and erosion of articular cartilage and enlargement of long bone metaphyses and costochondral junctions were seen radiographically and during post-mortem examination.¹⁵⁶ Microscopic changes were consistent with rickets and nutritional secondary hyperparathyroidism.¹⁵⁶ A similar case was reported on a semi-intensive pig farm in New Zealand where the pigs were fed a diet with no vitamin supplement.²⁰³ A combination of nutritional secondary hyperparathyroidism and rickets were seen histologically, with myelofibrosis and multifocal thickening of physes.²⁰³ No further cases were seen once fat-soluble vitamins (including vitamin D) were added to the diet.²⁰³

A genetic form of rickets similar to VDDR I in humans was originally described in pigs in 1962, and a strain (the Hannover) was bred with the syndrome. Pigs affected with VDDR I are used as a model for the same disease in humans.⁶⁴ From 3 to 8 weeks of age, piglets with VDDR I develop progressive hypocalcemia and hypophosphatemia, leading to secondary hyperparathyroidism and rickets.^{64,219} Concentrations of $1,25(\text{OH})_2\text{D}_3$ in the blood were low but significantly above zero, whereas concentrations of $25(\text{OH})\text{D}_3$ and PTH were high.^{64,104,219} Calcium-binding protein concentrations in the plasma and intestine were reduced, and no 25-hydroxyvitamin D_3 - 1α -hydroxylase and 24-hydroxylase activity was found in renal homogenates.⁶⁴

At the molecular level, VDDR I in the Hannover pig is associated with one of two different deletions in the *P450C1* coding region.³⁰ One involves a deletion of 173 base pairs and the other, a deletion of 329 base pairs, both of which lead to a frame shift mutation and a premature stop codon.³⁰ The result produces conformational changes that make the enzyme ineffectual owing to loss of the heme-binding region and other domains.³⁰ The authors hypothesized that a mRNA processing error may have caused the deletions, given that they occurred at mRNA processing sites.³⁰

Dogs

There are few reports of naturally occurring rickets in dogs and cats, and the disease is considered rare.¹⁰ Carnivores are unlikely to suffer from phosphorus deficiency given that phosphorus concentrations in meat are relatively high, and although they may not manufacture vitamin D in their skin, adequate levels of which are added to commercial rations.^{92,145,200} Dogs and cats fed predominantly meat- or offal-based rations without vitamin D supplements develop fibrous osteodystrophy rather than rickets, owing to nutritional secondary hyperparathyroidism.²⁰⁰

In the last 20 years, there have been three reports of rickets in dogs from Australia. Two involved litters of Greyhound pups and the other, a 12-week-old Collie.^{118,132} The Collie and one litter of Greyhounds were reared on a diet of milk and meat. The other Greyhound litter had an unreliable dietary

history.^{118,132} The age at presentation ranged from 10 weeks for the Collie to 14 weeks for one of the Greyhound litters.^{118,132} Clinical signs and radiographic changes in all dogs were considered to be consistent with rickets, but the diagnosis was not confirmed histologically. Serum $25(\text{OH})\text{D}$ concentrations were measured in one Greyhound litter and found to be low.¹³² The low concentration of vitamin D in milk, with the low maternal vitamin D status and the rapid growth of Greyhound pups, is thought to have predisposed these litters to rickets,¹³² but the possibility of fibrous osteodystrophy due to nutritional secondary hyperparathyroidism, either as an associated or a primary problem, was not excluded.

Rickets was reported in a Shetland Sheepdog diagnosed with acute renal failure at 10 weeks of age and fed a low phosphate renal failure diet.¹⁴¹ Ten weeks later, the dog presented with varus deformities of the forelimbs, failure to grow, and prominent metaphyses, and radiographically, it had widened physes.¹⁴¹ The renal failure diet had low protein and phosphate levels, which were inadequate for growth. Replacement of the diet with one specific for growing puppies led to resolution of clinical signs.¹⁴¹

In a recent report, VDDR I and suspected nutritional secondary hyperparathyroidism were diagnosed in an 8-month-old Shetland Sheepdog with diffuse osteopenia and myelopathy fed an organic premix and raw ground beef.¹⁹⁵ The term *vitamin D-dependent rickets type I* was used incorrectly in this case, given that this form of rickets is associated with a genetic defect in the activity of renal 1α -hydroxylase, rather than with a deficient diet. Rickets was diagnosed on the basis of low normal $25(\text{OH})\text{D}$,⁴⁵ but no growth plate changes were present radiographically,¹⁹⁵ so nutritional secondary hyperparathyroidism by itself may have been a more appropriate diagnosis.⁴⁵

HVDDR has been recently reported in a Pomeranian dog¹¹⁹ that had hypocalcemia, hyperparathyroidism, and skeletal abnormalities consistent with rickets. The dog's serum $25(\text{OH})\text{D}$ was low, whereas $1,25(\text{OH})_2\text{D}_3$ was increased, suggesting a VDR defect. In this case, a frame shift mutation was found in the VDR, which led to a premature stop codon and termination of protein translation.¹¹⁹

A possible inherited form of VDDR I was diagnosed in a Saint Bernard in Australia.⁹⁸ Serum calcium concentration was within normal limits; phosphorus concentration was low; and plasma PTH concentration was increased. Radiographs showed changes consistent with rickets. The authors considered a 25-hydroxyvitamin D - 1α -hydroxylase enzyme deficiency to be the most likely cause of the clinical signs seen in this dog,⁹⁸ but serum $25(\text{OH})\text{D}$ and $1,25(\text{OH})_2\text{D}_3$ concentrations were not measured and a diagnosis of VDDR I was not confirmed.

Cats

Naturally occurring rickets is rare in cats. Cats experimentally fed a vitamin D-deficient diet developed clinical signs of rickets after 4 and 5 months.⁴ The diagnosis of rickets was not confirmed histologically and was based on radiographic changes and increased serum alkaline phosphatase concentrations, which are not specific for rickets.

There has been one confirmed report of VDDR I and several reports of possible HVDRR in cats,^{71,72,79,175,194} but the diagnosis has not always been supported by adequate biochemical data or histology. In one case, confirmation of a diagnosis of HVDRR was obtained with skin biopsies for fibroblast culture to examine 1,25(OH)₂D₃ receptor binding, but genetic analysis was not performed.⁷² A 731delG mutation in the *CYP27B1* (1 α -hydroxylase) gene was detected in the case of VDDR I.⁷¹ Other reported cases appeared similarly. Most affected kittens presented at around 4 months of age, perhaps reflecting the time required for kittens born with normally mineralized bones to develop signs of vitamin D deficiency.⁸³ This assumes that transplacental calcium transport in cats does not require vitamin D. The kittens showed different responses to treatment, as seen in humans with HVDRR, presumably due to different defects in the VDR.¹³³

Reptiles

Metabolic bone disease is common in captive reptiles and typically manifests as a combination of fibrous osteodystrophy and osteomalacia in young actively growing animals.^{36,129,130} Factors associated with metabolic bone disease include dietary calcium deficiency, unbalanced calcium:phosphorus ratio in the diet, or inadequate exposure to ultraviolet light, leading to vitamin D deficiency.¹³⁰

The vitamin D endocrine system of reptiles appears to be similar to that of mammals.¹¹⁴ In the wild, reptiles have ample opportunity for sun basking, but in captivity, they may not have adequate exposure to natural light—for instance, iguanas held under ultraviolet lamps were shown to possess lower plasma vitamin D concentrations than iguanas exposed to natural light.¹¹⁶ The materials of the cage in which reptiles are kept may also attenuate ultraviolet light from lamps or natural light to below wavelengths required for vitamin D synthesis in the skin.²⁷ In the wild, reptiles alter their basking time, not only for thermoregulatory reasons, but also because of the vitamin D content of their diet.¹⁰² Chameleons given a diet low in vitamin D spent increased time basking compared to those fed a diet with adequate vitamin D.¹⁰²

Conclusion

Vitamin D is intimately involved in calcium and phosphate homeostasis, and it plays a crucial role in bone formation and remodeling. Deficiency of vitamin D in its active form, whether due to environmental or genetic factors, may result in rickets or osteomalacia secondary to hypocalcemia and hypophosphatemia. The hypocalcemia may also lead to hyperparathyroidism and concurrent fibrous osteodystrophy.

Although the gross and histologic lesions of rickets are characteristic, many reports of this disease in domestic animals are based on clinical signs and radiology and are thus questionable. Osteomalacia may be underdiagnosed in domestic animals because of the insensitivity of radiographs and an inability to reliably detect bone pain. It is important that veterinary

pathologists be aware of variations among species in their susceptibility to rickets and osteomalacia and thereby use objective criteria to confirm diagnoses.

Although vitamin D has long been recognized for its role in preventing rickets and osteomalacia in people and domestic animals, recent research has indicated that it may have important roles beyond the maintenance of a healthy skeleton. There is considerable potential for new and existing animal models to reveal further information about vitamin D metabolism and to investigate its possible involvement in immunity and cancer prevention.

Acknowledgement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interests with respect to the authorship and/or publication of this article.

Financial Disclosure/Funding

The authors received no financial support for the research and/or authorship of this article.

References

1. Agarwal KS, Mughal MZ, Upadhyay P, Berry JL, Mawer EB, Puliylal JM: The impact of atmospheric pollution on vitamin D status of infants and toddlers in Delhi, India. *Arch Dis Child* **87**:111–113, 2002.
2. Al-Jurayyan N, El-Desouki ME, Al-Herbish AS, Al-Mazyad AS, Al-Qhtani MM: Nutritional rickets and osteomalacia in school children and adolescents. *Saudi Med J* **23**:182–185, 2002.
3. Anderson PH, Atkins GJ: The skeleton as an intracrine organ for vitamin D metabolism. *Mol Aspects Med* **29**:397–406, 2008.
4. Anonymous: Vitamin D deficiency in the cat. *Nutr Rev* **16**:140–141, 1958.
5. Azam N, Zhang MYH, Wang XM, Tenenhouse HS, Portale AA: Disordered regulation of renal 25-hydroxyvitamin D-1 α -hydroxylase gene expression by phosphorus in X-linked hypophosphatemic (Hyp) mice. *Endocrinology* **144**:3463–3468, 2003.
6. Bai X-Y, Miao D, Goltzman D, Karaplis AC: The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. *J Biol Chem* **276**:9843–9849, 2003.
7. Barsony J, Prufer K: Vitamin D receptor and retinoid \times receptor interactions in motion. *Vitam Horm* **65**:345–376, 2002.
8. Batchelor AJ, Compston JE: Reduced plasma half-life of radio-labelled 25-hydroxyvitamin D₃ in subjects receiving a high-fibre diet. *Br J Nutr* **49**:213–216, 1983.
9. Beckman MJ, Tadikonda P, Werner E, Prah J, Yamada S, DeLuca HF: Human 25-hydroxyvitamin D₃-24-hydroxylase, a multicatalytic enzyme. *Biochemistry* **35**:8465–8472, 1996.
10. Bennett D: Nutrition and bone disease in the dog and cat. *Vet Rec* **98**:313–320, 1976.
11. Bergwitz C, Roslin NM, Tieder M, Loredano-Osti JC, Bastepe M, Abu-Zahra H, Frappier D, Burkett K, Carpenter TO, Anderson

- D, Garabédian M, Sermet I, Fujiwara TM, Morgan K, Tenenhouse HS, Jüppner H: SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaP_i-IIc in maintaining phosphate homeostasis. *Am J Hum Genet* **78**:179–192, 2006.
12. Berndt TJ, Schiavi S, Kumar R: “Phosphatonins” and the regulation of phosphorus homeostasis. *Am J Physiol Renal Physiol* **289**:F1170–F1182, 2005.
13. Best CH, Taylor NB: The vitamins. *In: The Physiological Basis of Medical Practice*, 2nd ed., pp. 1019–1042. Williams & Wilkins Company, Baltimore, MD, 1939.
14. Bielez B, Klaushofer K, Oberbauer R: Renal phosphate loss in hereditary and acquired disorders of bone mineralization. *Bone* **35**:1229–1239, 2004.
15. Bikle D: Nonclassic actions of vitamin D. *J Clin Endocrinol Metab* **94**:26–34, 2009.
16. Bonniwell MA, Smith BSW, Spence JA, Wright H, Ferguson DAM: Rickets associated with vitamin D deficiency in young sheep. *Vet Rec* **122**:386–388, 1988.
17. Boros S, Bindels R, Hoenderop J: Active Ca²⁺ reabsorption in the connecting tubule. *Pflugers Arch* **458**:99–109, 2009.
18. Bouillon R, Van Cromphaut S, Carmeliet G: Intestinal calcium absorption: molecular vitamin D mediated mechanisms. *J Cell Biochem* **88**:332–339, 2003.
19. Boyce BF, Xing L: Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Arch Biochem Biophys* **473**:139–146, 2008.
20. Breidenbach A, Schlumbohm C, Harmeyer J: Peculiarities of vitamin D and of the calcium and phosphate homeostatic system in horses. *Vet Res* **29**:173–186, 1998.
21. Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, Suda T, DeLuca HF: Parathyroid hormone activation of the 25-hydroxyvitamin D₃-1 α -hydroxylase gene promoter. *Proc Natl Acad Sci U S A* **95**:1387–1391, 1998.
22. Brock K, Wilkinson M, Cook R, Lee S, Birmingham M: Associations with vitamin D deficiency in “at risk” Australians. *J Steroid Biochem Mol Biol* **89–90**:581–588, 2004.
23. Brooks MH, Bell NH, Love L, Stern PH, Orfei E, Queener SF, Hamstra AJ, DeLuca HF: Vitamin-D-dependent rickets type II: resistance of target organs to 1,25-dihydroxyvitamin D. *N Engl J Med* **298**:996–999, 1978.
24. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, Slatopolsky E: Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. *Am J Physiol Renal Physiol* **270**:F454–F460, 1996.
25. Bryant FC, Farfan RD: Dry season forage selection by Alpaca (*Lama pacos*) in Southern Peru. *J Range Manag* **37**:330–333, 1984.
26. Bula CM, Huhtakangas J, Olivera C, Bishop JE, Norman AW, Henry HL: Presence of a truncated form of the vitamin D receptor (VDR) in a strain of VDR-knockout mice. *Endocrinology* **146**:5581–5586, 2005.
27. Burger RM, William HG, Gary WF: Evaluation of UVB reduction by materials commonly used in reptile husbandry. *Zoo Biol* **26**:417–423, 2007.
28. Canaff L, Hendy GN: Human calcium-sensing receptor gene: vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. *J Biol Chem* **277**:30337–30350, 2002.
29. Chaudhary MS, Care AD: Production of vitamin D₃ in sheep in response to artificial ultraviolet light exposure. *In: Proceedings of the Sixth Workshop on Vitamin D*, Merano, Italy: Vitamin D. A Chemical, Biochemical and Clinical Update, ed. Norman AW, Schaefer K, Grigoleit HG, Herrath D, pp. 711–712. Walter de Gruyter, Berlin, Germany, 1985.
30. Chavez LS, Serda R, Choe S, Davidi L, Harmeyer J, Omdahl JL: Molecular basis for pseudo vitamin D–deficiency rickets in the Hannover pig. *J Nutr Biochem* **14**:378–385, 2003.
31. Chen H, Hewison M, Adams JS: Functional characterization of heterogenous nuclear ribonuclear protein C1/C2 in vitamin D resistance: a novel response element-binding protein. *J Biol Chem* **281**:39114–39120, 2006.
32. Chen H, Hewison M, Hu B, Adams JS: Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: a cause of vitamin D resistance. *Proc Natl Acad Sci U S A* **100**:6109–6114, 2003.
33. Chen H, Hu B, Allegretto EA, Adams JS: The vitamin D response element-binding protein: a novel dominant-negative regulator of vitamin D–directed transactivation. *J Biol Chem* **275**:35557–35564, 2000.
34. Chesney RW: Rickets: an old form for a new century. *Pediatr Int* **45**:509–511, 2003.
35. Chun RF, Chen H, Boldrick L, Sweet C, Adams JS: Cloning, sequencing, and functional characterization of the vitamin D receptor in vitamin D–resistant new world primates. *Am J Primatol* **54**:107–118, 2001.
36. Cowan DF: Diseases of captive reptiles. *J Am Vet Med Assoc* **153**:848–859, 1968.
37. Crowley JP: Rickets in november-born lambs. *Vet Rec* **73**:295–297, 1961.
38. Dardenne O, Prud’homme J, Arabian A, Glorieux FH, St-Arnaud R: Targeted inactivation of the 25-hydroxyvitamin D₃-1 α -hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D–deficiency rickets. *Endocrinology* **142**:3135–3141, 2001.
39. Davis CD: Vitamin D and cancer: current dilemmas and future research needs. *Am J Clin Nutr* **88**:565S–569S, 2008.
40. DeLuca HF: Overview of general physiologic features and functions of vitamin D. *Am J Clin Nutr* **80**:1689S–1696S, 2004.
41. Demay MB: Mechanism of vitamin D receptor action. *Ann N Y Acad Sci* **1068**:204–213, 2006.
42. Dercksen DP, Berger JM: Rickets-like bone changes in goat kids fed with artificial milk intended for calves. *Tijdschr Diergeneesk* **117**:629–631, 1992.
43. Dhawan P, Peng X, Sutton ALM, MacDonald PN, Croniger CM, Trautwein C, Centrella M, McCarthy TL, Christakos S: Functional cooperation between CCAAT/enhancer-binding proteins and the vitamin D receptor in regulation of 25-hydroxyvitamin D₃ 24-hydroxylase. *Mol Cell Biol* **25**:472–487, 2005.
44. Dittmer KE: Disease inheritance. *In: Inherited Rickets in Corriedale Sheep* [PhD dissertation], pp. 83–95. Massey University, Palmerston North, New Zealand, 2008.
45. Dittmer KE, Thompson KG: Questions term used in study on raw meat-based diets. *J Am Vet Med Assoc* **235**:817, 2009.

46. Dittmer KE, Thompson KG, Blair HT: Pathology of inherited rickets in Corriedale sheep. *J Comp Pathol* **141**:147–155, 2009.
47. Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B: cDNA cloning of the murine *Pex* gene implicated in X-linked hypophosphatemia and evidence for expression in bone. *Genomics* **36**:22–28, 1996.
48. Duckworth J, Benzie E, Cresswell E, Hill R, Dalgarno AC, Robinson JF, Robson HW: Dental mal-occlusion and rickets in sheep. *Res Vet Sci* **2**:375–380, 1961.
49. Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. *Am J Physiol Renal Physiol* **289**:F8–F28, 2005.
50. Dusso AS, Thadhani R, Slatopolsky E: Vitamin D receptor and analogs. *Semin Nephrol* **24**:10–16, 2004.
51. Edwards DJ, Brownlow MA, Hutchins DR: Indices of renal function: reference values in normal horses. *Aust Vet J* **66**:60–63, 1989.
52. Eicher EM, Southard JL, Scriver CR, Glorieux FH: Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. *Proc Natl Acad Sci U S A* **73**:4667–4671, 1976.
53. El Shorafa WM, Feaster JP, Ott EA, Asquith RL: Effect of vitamin D and sunlight on growth and bone development of young ponies. *J Anim Sci* **48**:882–886, 1979.
54. Erben RG, Soegiarto DW, Weber K, Zeitz U, Lieberherr M, Gniedeki R, Moller G, Adamski J, Balling R: Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. *Mol Endocrinol* **16**:1524–1537, 2002.
55. Ewer TK: Rickets in sheep: field trials in East Anglia. *Vet Rec* **62**:603–606, 1950.
56. Ewer TK: Vitamin D requirements of sheep. *Aust Vet J* **29**:310–315, 1953.
57. Ewer TK, Bartrum P: Rickets in sheep. *Aust Vet J* **24**:73–85, 1948.
58. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE: Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. *Nat Genet* **38**:1310–1315, 2006.
59. Fitch LWN: A note on the storage of vitamin D by sheep following the subcutaneous administration of a single massive dose of calciferol. *Aust Vet J* **20**:303–304, 1944.
60. Fitch LWN: Osteodystrophic diseases of sheep in New Zealand: I. Rickets in hoggets: with a note on the aetiology and definition of the disease. *Aust Vet J* **19**:2–20, 1943.
61. Fitch LWN, Ewer TK: The value of vitamin D and bone-flour in the prevention of rickets in sheep in New Zealand. *Aust Vet J* **20**:220–226, 1944.
62. Folpe A, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O'Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Venh TN, Wold LE, Wehril BM, White KE, Zaino RJ, Weiss SW: Most osteomalacia-associated mesenchymal tumours are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. *Am J Surg Pathol* **28**:1–30, 2004.
63. Fox AT, Du Toit G, Lang A, Lack G: Food allergy as a risk factor for nutritional rickets. *Pediatr Allergy Immunol* **15**:566–569, 2004.
64. Fox J, Maunder EM, Randall VA, Care AD: Vitamin D-dependent rickets type I in pigs. *Clin Sci* **69**:541–548, 1985.
65. Fraser D, Kooh SW, Kind HP, Holick MF, Tanaka Y, DeLuca HF: Pathogenesis of hereditary vitamin-D-dependent rickets: an inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 α ,25-dihydroxyvitamin D. *N Engl J Med* **289**:817–822, 1973.
66. Friedman PA, Gesek FA: Vitamin D₃ accelerates PTH-dependent calcium transport in distal convoluted tubule cells. *Am J Physiol Renal Physiol* **265**:F300–F308, 1993.
67. Fu GK, Lin D, Zhang MYH, Bikle DD, Shackleton CHL, Miller WL, Portale AA: Cloning of human 25-hydroxyvitamin D-1 α -hydroxylase and mutations causing vitamin D-dependent rickets type I. *Mol Endocrinol* **11**:1961–1970, 1997.
68. Fujiwara I, Aravindan R, Horst RL, Drezner MK: Abnormal regulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in X-linked hypophosphatemia: a translational or post-translational defect. *J Bone Miner Res* **18**:434–442, 2003.
69. Garland CF, Gorham ED, Mohr SB, Garland FC: Vitamin D for cancer prevention: global perspective. *Ann Epidemiol* **19**:468–483, 2009.
70. Garner SC, Pi M, Tu Q, Quarles LD: Rickets in cation-sensing receptor-deficient mice: An unexpected skeletal phenotype. *Endocrinology* **142**:3996–4005, 2001.
71. Geisen V, Weber K, Hartmann K: Vitamin D-dependent hereditary rickets type I in a cat. *J Vet Intern Med* **23**:196–199, 2009.
72. Godfrey DR, Anderson RM, Barber PJ, Hewison M: Vitamin D-dependent rickets type II in a cat. *J Small Anim Pract* **46**:440–444, 2005.
73. Goltzman D, Miao DS, Panda DK, Hendy GN: Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. *J Steroid Biochem Mol Biol* **89–90**:485–489, 2004.
74. Grant AB, O'Hara PB: The rachitogenic effect of vitamin A. *N Z J Sci Technol A* **38**:548–576, 1957.
75. Gunther R, Felice LJ, Nelson RK, Franson AM: Toxicity of a vitamin D₃ rodenticide to dogs. *J Am Vet Med Assoc* **193**:211–214, 1988.
76. Hannam S, Lee S, Sellars M: Severe vitamin D deficient rickets in black Afro-Caribbean children. *Arch Dis Child* **89**:91–92, 2004.
77. Hatun S, Ozkan B, Orbak Z, Doneray H, Cizmecioglu F, Toprak D, Calikoglu AS: Vitamin D deficiency in early infancy. *J Nutr* **135**:279–282, 2005.
78. Haussler MR, Whitfield GK, Haussler CA, Hsieh J-C, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. *J Bone Miner Res* **13**:325–349, 1998.
79. Henik RA, Forrest LJ, Friedman AL: Rickets caused by excessive renal phosphate loss and apparent abnormal vitamin D metabolism in a cat. *J Am Vet Med Assoc* **215**:1644–1649, 1999.
80. Hewison M, Rut AR, Kristjansson K, Walker RE, Dillon MJ, Hughes MR, O'Riordan JLH: Tissue resistance to 1,25-dihydroxyvitamin D without a mutation of the vitamin D receptor gene. *Clin Endocrinol (Oxf)* **39**:663–670, 1993.

81. Hidioglou M, Williams CJ, Proulx JG: Plasma vitamin D₃ response in cattle and sheep exposed to ultraviolet radiation. *Int J Vitam Nutr Res* **55**:41–46, 1985.
82. Hill FI, Thompson KG, Grace ND: Rickets in alpacas (*Lama pacos*) in New Zealand. *N Z Vet J* **42**:229–232, 1994.
83. Hochberg Z: Vitamin-D-dependent rickets type 2. *Horm Res* **58**:297–302, 2002.
84. Hoenderop JGJ, Dardenne O, Van Abel M, Van Der Kemp AWCM, Van Os CH, St-Arnaud R, Bindels RJM: Modulation of renal Ca²⁺ transport protein genes by dietary Ca²⁺ and 1,25-dihydroxyvitamin D₃ in 25-hydroxyvitamin D₃-1 α -hydroxylase knockout mice. *FASEB J* **16**:1398–1406, 2002.
85. Hoenderop JGJ, Muller D, Van der Kemp AWCM, Hartog A, Suzuki M, Ishibashi K, Imai M, Sweep F, Willems PHGM, Van Os CH, Bindels RJM: Calcitriol controls the epithelial calcium channel in kidney. *J Am Soc Nephrol* **12**:1342–1349, 2001.
86. Hoenderop JGJ, Nilius B, Bindels RJM: Calcium absorption across epithelia. *Physiol Rev* **85**:373–422, 2005.
87. Holick MF: The cutaneous photosynthesis of previtamin D₃: a unique photoendocrine system. *J Invest Dermatol* **77**:51–58, 1981.
88. Holick MF: Vitamin D: A millenium perspective. *J Cell Biochem* **88**:296–307, 2003.
89. Holick MF: Vitamin D: Photobiology, metabolism, mechanism of action and clinical applications. *In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, ed. Favus MJ, 4th ed., pp. 92–98. Lippincott Williams & Wilkins, Philadelphia, PA, 1999.
90. Holick MF, Chen TC, Lu Z, Sauter E: Vitamin D and skin physiology: a d-lightful story. *J Bone Miner Res* **22**:V28–V33, 2007.
91. Holvik K, Meyer HE, Haug E, Brunvand L: Prevalence and predictors of vitamin D deficiency in five immigrant groups living in Oslo, Norway: the Oslo Immigrant Health Study. *Eur J Clin Nutr* **59**:57–63, 2005.
92. How KL, Hazewinkel HAW, Mol JA: Dietary vitamin D dependence of cat and dog due to inadequate cutaneous synthesis of vitamin D. *Gen Comp Endocrinol* **96**:12–18, 1994.
93. Huh SY, Gordon CM: Vitamin D deficiency in children and adolescents: epidemiology, impact and treatment. *Rev Endocr Metab Disord* **9**:161–170, 2008.
94. Ichikawa S, Traxler EA, Estwick SA, Curry LR, Johnson ML, Sorenson AH, Imel EA, Econs MJ: Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets. *Bone* **43**:663–666, 2008.
95. Imataka G, Mikami T, Yamanouchi H, Kano K, Eguchi M: Vitamin D deficiency rickets due to soybean milk. *J Paediatr Child Health* **40**:154–155, 2004.
96. Jehan-Kimmel C, Darwish HM, Strugnelli SA, Jehan F, Wiefeling B, DeLuca HF: DNA bending is induced by binding of vitamin D receptor-retinoid X receptor heterodimers to vitamin D responsive elements. *J Cell Biochem* **74**:220–228, 1999.
97. Johansson S, Melhus H: Vitamin A antagonizes calcium response to vitamin D in man. *J Bone Miner Res* **16**:1899–1905, 2001.
98. Johnson KA, Church DB, Barton RJ, Wood AKW: Vitamin D-dependent rickets in a Saint Bernard dog. *J Small Anim Pract* **29**:657–666, 1988.
99. Jones G: Pharmacokinetics of vitamin D toxicity. *Am J Clin Nutr* **88**:582S–586S, 2008.
100. Jones G, Strugnelli SA, DeLuca HF: Current understanding of the molecular actions of vitamin D. *Physiol Rev* **78**:1193–1231, 1998.
101. Jonsson G, Jacobsson S-O, Stromberg B, Olsson S-E, Bjorklund N-E: Rickets and secondary nutritional hyperparathyroidism: a clinical syndrome in fattening bulls. *Acta Radiol Suppl (Stockholm)* **319**:91–105, 1972.
102. Karsten KB, Ferguson GW, Chen TC, Holick MF: Panther chameleons, *Furcifer pardalis*, behaviorally regulate optimal exposure to UV depending on dietary vitamin D₃ status. *Physiol Biochem Zool* **82**:218–225, 2009.
103. Kasuga H, Hosogane N, Matsuoka K, Mori I, Sakura Y, Shimakawa K, Shinki T, Suda T, Taketomi S: Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. *Biochem Biophys Res Commun* **297**:1332–1338, 2002.
104. Kaune R, Harmeyer J: Vitamin D₃ metabolism in a pig strain with pseudo vitamin D-deficiency rickets, type I. *Acta Endocrinol (Copenh)* **115**:345–352, 1987.
105. Khandare AL, Harikuma R, Sivakumar B: Severe bone deformities in young children from vitamin D deficiency and fluorosis in Bihar-India. *Calcif Tissue Int* **76**:412–418, 2005.
106. Kitanaka S, Takeyama K-I, Murayama A, Kato S: The molecular basis of vitamin D-dependent rickets type I. *Endocr J* **48**:427–432, 2001.
107. Kitanaka S, Takeyama K, Murayama A, Sato T, Okumura K, Nogami M, Hasegawa Y, Niimi H, Yanagisawa J, Tanaka T, Kato S: Inactivating mutations in the 25-hydroxyvitamin D₃1 α -hydroxylase gene in patients with pseudovitamin D-deficiency rickets. *N Engl J Med* **338**:653–661, 1998.
108. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R: Vitamin D₃ supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. *J Cell Biochem* **89**:771–777, 2003.
109. Klein GL: Nutritional rickets and osteomalacia. *In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, ed. Favus MJ, 4th ed., pp. 315–319. Lippincott Williams & Wilkins, Philadelphia, PA, 1999.
110. Kondo T, Kitazawa R, Maeda S, Kitazawa S: 1 α ,25 Dihydroxyvitamin D₃ rapidly regulates the mouse osteoprotegerin gene through dual pathways. *J Bone Miner Res* **19**:1411–1419, 2004.
111. Krishnan AV, Peehl DM, Feldman D: Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. *J Cell Biochem* **88**:363–371, 2003.
112. Kurland ES, Schulman RC, Zerwekh JE, Reinus WR, Dempster DW, Whyte MP: Recovery from skeletal fluorosis (an enigmatic, American case). *J Bone Miner Res* **22**:163–170, 2007.
113. Kurnik BRC, Hruska KA: Mechanism of stimulation of renal phosphate transport by 1,25-dihydroxycholecalciferol. *Biochim Biophys Acta* **817**:42–50, 1985.
114. Laing CJ, Fraser DR: The vitamin D system in iguanian lizards. *Comp Biochem Physiol B Biochem Mol Biol* **123**:373–379, 1999.

115. Laing CJ, Malik R, Wigney DI, Fraser DR: Seasonal vitamin D status of greyhounds in Sydney. *Aust Vet J* **77**:35–38, 1999.
116. Laing CJ, Trube A, Shea GM, Fraser DR: The requirement for natural sunlight to prevent vitamin D deficiency in iguanian lizards. *J Zoo Wildl Med* **32**:342–348, 2009.
117. Lammi-Keefe CJ: Vitamins D and E in human milk. *In: Handbook of Milk Composition*, ed. Jensen RG, pp. 706–717. Academic Press, Inc, San Diego, CA, 1995.
118. Lavelle RB: Hypocalcemic tetany in association with rickets in the dog. *Vet Radiol* **29**:190, 1988.
119. LeVine DN, Zhou Y, Ghiloni RJ, Fields EL, Birkenheuer AJ, Gookin JL, Roberston ID, Malloy PJ, Feldman D: Hereditary 1,25-dihydroxyvitamin d-resistant rickets in a Pomeranian dog caused by a novel mutation in the vitamin D receptor gene. *J Vet Intern Med* **23**:1278–1283, 2009.
120. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. *Endocrinology* **139**:4391–4396, 1998.
121. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay MB: Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. *Proc Natl Acad Sci U S A* **94**:9831–9835, 1997.
122. Liberman UA, Marx SJ: Vitamin D and other calciferols. *In: The Metabolic and Molecular Bases of Inherited Disease*, ed. Scriver CR, Beaudet AL, Sly WS, Valle D, 8th ed., pp. 4223–4240. McGraw-Hill Co, Inc, New York, 2001.
123. Liu S, Quarles LD: How fibroblast growth factor 23 works. *J Am Soc Nephrol* **18**:1637–1647, 2007.
124. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD: Pathogenic role of Fgf23 in Hyp mice. *Am J Physiol Endocrinol Metab* **291**:E38–E49, 2006.
125. Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD: Pathogenic role of Fgf23 in *Dmp1*-null mice. *Am J Physiol Endocrinol Metab* **295**:E254–E261, 2008.
126. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM: DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. *Nat Genet* **38**:1248–1250, 2006.
127. Lyon MF, Scriver CR, Baker LRI, Tenenhouse HS, Kronick J, Mandla S: The Gy mutation: another cause of X-linked hypophosphatemia in mouse. *Proc Natl Acad Sci U S A* **83**:4899–4903, 1986.
128. MacLaughlin J, Holick MF: Aging decreases the capacity of human skin to produce vitamin D₃. *J Clin Invest* **76**:1536–1538, 1985.
129. Mader DR: Metabolic bone disease. *In: Reptile medicine and surgery*, ed. Mader DR, 2nd ed., pp. 841–851. Elsevier Inc, St Louis, MO, 2006.
130. Mader DR: Nutritional secondary hyperparathyroidism in green iguanas. *Kirk's Curr Vet Ther* **8**:1179–1182, 2000.
131. Maenpaa PH, Koskinen T, Koskinen E: Serum profiles of vitamins A, E and D in mares and foals during different seasons. *J Anim Sci* **66**:1418–1423, 1988.
132. Malik R, Laing C, Davis PE, Allan GS, Wigney DI: Rickets in a litter of racing greyhounds. *J Small Anim Pract* **38**:109–114, 1997.
133. Malloy PJ, Pike JW, Feldman D: The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. *Endocr Rev* **20**:156–188, 1999.
134. Mankin HJ: Metabolic bone disease. *J Bone Joint Surg Am* **76**:760–788, 1994.
135. Marx SJ, Spiegel AM, Brown EM, Gardner DG, Downs Jr RW, Attie M, Hamstra AJ, DeLuca HF: A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D. *J Clin Endocrinol Metab* **47**:1303–1310, 1978.
136. Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G: Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. *J Clin Invest* **116**:3150–3159, 2006.
137. Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF: Sunscreens suppress cutaneous vitamin D₃ synthesis. *J Clin Endocrinol Metab* **64**:1165–1168, 1987.
138. Matsuoka LY, Wortsman J, Dannenberg MJ, Hollis BW, Lu Z, Holick MF: Clothing prevents ultraviolet-B radiation-dependent photosynthesis of vitamin D₃. *J Clin Endocrinol Metab* **75**:1099–1103, 1992.
139. McCarthy EF, Frassica FJ: Metabolic bone diseases. *In: Pathology of Bone and Joint Disorders with Clinical and Radiographic Correlation*, pp. 75–103. WB Saunders Company, Philadelphia, PA, 1998.
140. McKenna MJ: Differences in vitamin D status between countries in young adults and the elderly. *Am J Med* **93**:69–77, 1992.
141. McMillan CJ, Griffon DJ, Marks SL, Mauldin GE: Dietary-related skeletal changes in a Shetland Sheepdog puppy. *J Am Anim Hosp Assoc* **42**:57–64, 2006.
142. Mearns R, Scholes SFE, Wessels M, Whitaker K, Strugnell B: Rickets in sheep flocks in northern England. *Vet Rec* **162**:98–99, 2008.
143. Meyer MB, Watanuki M, Kim S, Shevde NK, Pike JW: The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D₃ in intestinal cells. *Mol Endocrinol* **20**:1447–1461, 2006.
144. Milgram JW: Renal osteodystrophy. *In: Radiologic and Histologic Pathology of Nontumorous Diseases of Bones and Joints*, ed. Milgram JW, pp. 745–778. Northbrook Publishing Company Co, Inc, Northbrook, IL, 1990.
145. Morris JG: Ineffective vitamin D synthesis in cats is reversed by an inhibitor of 7-dehydrocholesterol- Δ^7 -reductase. *J Nutr* **129**:903–908, 1999.
146. Muller K, Bendtzen K: Role of 1,25-dihydroxyvitaminD₃ (1,25(OH)₂D₃) as modulator of immunoinflammatory reactions. *In: Vitamin D: Gene Regulation, Structure-Function Analysis and Clinical Application*, pp. 498–499. Walter de Gruyter, New York, NY, 1991.
147. Murayama A, Takeyama K, Kitanaka S, Kodera Y, Hosoya T, Kato S: The promoter of the human 25-hydroxyvitamin D₃ 1 α -hydroxylase gene confers positive and negative responsiveness

- to PTH, calcitonin, and $1\alpha,25(\text{OH})_2\text{D}_3$. *Biochem Biophys Res Commun* **249**:11–16, 1998.
148. Murphy MJ: Rodenticides. *Vet Clin North Am Small Anim Pract* **32**:469–484, 2002.
149. Naja RP, Dardenne O, Arabian A, St Arnaud R: Chondrocyte-specific modulation of Cyp27b1 expression supports a role for local synthesis of $1,25$ -dihydroxyvitamin D₃ in growth plate development. *Endocrinology* **150**:4024–4032, 2009.
150. Nisbet DI, Butler EJ, Smith BSW, Robertson JM, Bannatyne CC: Osteodystrophic diseases of sheep: II. Rickets in young sheep. *J Comp Pathol* **76**:159–169, 1966.
151. Noimark L, Cox HE: Nutritional problems related to food allergy in childhood. *Pediatr Allergy Immunol* **19**:188–195, 2008.
152. Panda DK, Miao DS, Bolivar I, Li JR, Huo RJ, Hendy GN, Goltzman D: Inactivation of the 25-hydroxyvitamin D 1α -hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. *J Biol Chem* **279**:16754–16766, 2004.
153. Panda DK, Miao DS, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D: Targeted ablation of the 25-hydroxyvitamin D 1α -hydroxylase enzyme: evidence for skeletal reproductive, and immune dysfunction. *Proc Natl Acad Sci U S A* **98**:7498–7503, 2001.
154. Parton K, Bruere AN, Chambers JP: *Veterinary Clinical Toxicology*, 2nd ed., p. 397. Foundation for Continuing Education of the NZ Veterinary Association, Massey University, Palmerston North, New Zealand, 2001.
155. Pedersen P, Michaelsen KF, Molgaard C: Children with nutritional rickets referred to hospitals in Copenhagen during a 10-year period. *Acta Paediatr* **92**:87–90, 2003.
156. Pepper TA, Bennett D, Brown PJ, Taylor DJ: Rickets in growing pigs and response to treatment. *Vet Rec* **103**:4–8, 1978.
157. Pettifor JM: Rickets. *Calcif Tissue Int* **70**:398–399, 2002.
158. Pettifor JM: Rickets and vitamin D deficiency in children and adolescents. *Endocrinol Metab Clin North Am* **34**:537–553, 2005.
159. Pettifor JM, Moodley GP, Hough FS, Koch H, Chen T, Lu Z, Holick MF: The effect of season and latitude on in vitro vitamin D formation by sunlight in South Africa. *S Afr Med J* **86**:1270–1272, 1996.
160. Pitt MJ: Rickets and osteomalacia. In: *Diagnosis of Bone and Joint Disorders*, ed. Resnick D, 3 ed., pp. 1885–1922. WB Saunders Co, Philadelphia, PA, 1995.
161. Prince RL, Glendenning P: *MJA practice essentials: endocrinology*. 8: disorders of bone and mineral other than osteoporosis. *Med J Aust* **180**:354–359, 2004.
162. Prosser DE, Jones G: Enzymes involved in the activation and inactivation of vitamin D. *Trends Biochem Sci* **29**:664–673, 2004.
163. Quack M, Carlberg C: The impact of functional vitamin D₃ receptor conformations on DNA-dependent vitamin D₃ signaling. *Mol Pharmacol* **57**:375–384, 2000.
164. Rachez C, Freedman LP: Mechanisms of gene regulation by vitamin D₃ receptor: a network of coactivator interactions. *Gene* **246**:9–21, 2000.
165. Rajakumar K: Vitamin D, cod-liver oil, sunlight, and rickets: A historical perspective. *Pediatrics* **112**:E132–E133, 2003.
166. Ramasamy I: Inherited disorders of calcium homeostasis. *Clin Chim Acta* **394**:22–41, 2008.
167. Reeve LE, Chesney RW, DeLuca HF: Vitamin D of human milk: identification of biologically active forms. *Am J Clin Nutr* **36**:122–126, 1982.
168. Ritz E, Haxsen V, Zeier M: Disorders of phosphate metabolism: pathomechanisms and management of hypophosphataemic disorders. *Best Pract Res Clin Endocrinol Metab* **17**:547–558, 2003.
169. Rohde CM, Manatt M, Clagett-Dame M, DeLuca HF: Vitamin A antagonizes the action of vitamin D in rats. *J Nutr* **129**:2246–2250, 1999.
170. Rose AL: Osteomalacia in the Northern Territory. *Aust Vet J* **172**:172–177, 1954.
171. Rost CR, Bikle DD, Kaplan RA: In vitro stimulation of 25-hydroxycholecalciferol 1α -hydroxylation by parathyroid hormone in chick kidney slices: evidence for a role for adenosine 3',5'-monophosphate. *Endocrinology* **108**:1002–1006, 1981.
172. Rowe PSN: The wrickkened pathways of FGF23, MEPE and PHEX. *Crit Rev Oral Biol Med* **15**:264–281, 2004.
173. Safadi FF, Thornton P, Magiera H, Hollis BW, Gentile M, Haddad JG, Liebhaber SA, Cooke NE: Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. *J Clin Invest* **103**:239–251, 1999.
174. Scheftel J, Setzer S, Walser M, Pertile T, Hegstad RL, Felice LJ, Murphy MJ: Elevated 25-hydroxy and normal $1,25$ -dihydroxy cholecalciferol serum concentrations in a successfully-treated case of vitamin D₃ toxicosis in a dog. *Vet Hum Toxicol* **33**:345–348, 1991.
175. Schreiner CA, Nagode LA: Vitamin D-dependent rickets type 2 in a four-month-old cat. *J Am Vet Med Assoc* **222**:337–339, 2003.
176. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *J Bone Miner Res* **19**:429–435, 2004.
177. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of *Fgf23* demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. *J Clin Invest* **113**:561–568, 2004.
178. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. *Endocrinology* **143**:3179–3182, 2002.
179. Shinki T, Shiina Y, Takahashi N, Tanioka Y, Koizumi H, Suda T: Extremely high circulating levels of $1\alpha,25$ -dihydroxyvitamin D₃ in the marmoset, a new world monkey. *Biochem Biophys Res Commun* **114**:452–457, 1983.
180. Shupe JL, Butcher JE, Call JW, Olson AE, Blake JT: Clinical signs and bone changes associated with phosphorus deficiency in beef cattle. *Am J Vet Res* **49**:1629–1636, 1988.

181. Sitrin M, Meredith S, Rosenberg IH: Vitamin D deficiency and bone disease in gastrointestinal disorders. *Arch Intern Med* **138**:886–888, 1978.
182. Smith BB, Van Saun RJ: Seasonal changes in serum calcium, phosphorus, and vitamin D concentrations in llamas and alpacas. *Am J Vet Res* **62**:1187–1193, 2001.
183. Smith BSW, Wright H: 25-hydroxyvitamin D concentrations in equine serum. *Vet Rec* **115**:579, 1984.
184. Smith BSW, Wright H: Seasonal variation in serum 25-hydroxyvitamin D concentrations in sheep. *Vet Rec* **109**:139–141, 1981.
185. Smith BSW, Wright H, Brown KG: Effect of vitamin D supplementation during pregnancy on the vitamin D status of ewes and their lambs. *Vet Rec* **120**:199–201, 1987.
186. Spratling FR, Bridge PS, Rest JR, Cruickshank EM: Osteodystrophy associated with apparent hypovitaminosis-D in yearling cattle. *Br Vet J* **126**:316–323, 1970.
187. St-Arnaud R: The direct role of vitamin D on bone homeostasis. *Arch Biochem Biophys* **473**:225–230, 2008.
188. St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, Depovere J, Mathieu C, Christakos S, Demay MB, Glorieux FH: Deficient mineralisation of intramembranous bone in vitamin D–24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. *Endocrinology* **141**:2658–2666, 2000.
189. Suda T, Ueno Y, Fujii K, Shinki T: Vitamin D and bone. *J Cell Biochem* **88**:259–266, 2003.
190. Suzuki Y, Landowski CP, Hediger MA: Mechanisms and regulation of epithelial Ca²⁺ absorption in health and disease. *Annu Rev Physiol* **70**:3.1–3.15, 2008.
191. Takeda S, Yoshizawa T, Nagai Y, Yamato H, Fukumoto S, Sekine K, Kato S, Matsumoto T, Fujita T: Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: Studies using VDR knockout mice. *Endocrinology* **140**:1005–1008, 1999.
192. Tanaka Y, DeLuca HF: The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. *Arch Biochem Biophys* **154**:566–574, 1973.
193. Tanaka Y, Lorenc RS, DeLuca HF: The role of 1,25-dihydroxyvitamin D₃ and parathyroid hormone in the regulation of chick renal 25-hydroxyvitamin D₃-24-hydroxylase. *Arch Biochem Biophys* **171**:521–526, 1975.
194. Tanner E, Langley-Hobbs SJ: Vitamin D–dependent rickets type 2 with characteristic radiographic changes in a 4-month-old kitten. *J Feline Med Surg* **7**:307–311, 2005.
195. Taylor MB, Geiger DA, Saker KE, Larson MM: Diffuse osteopenia and myelopathy in a puppy fed a diet composed of an organic premix and raw ground beef. *J Am Vet Med Assoc* **234**:1041–1048, 2009.
196. The ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in *FGF23*. The ADHR Consortium. *Nat Genet* **26**:345–348, 2000.
197. Theiler A: The osteodystrophic diseases of domesticated animals: 2. Rickets and osteomalacia. *Vet J* **90**:159–175, 1934.
198. Theiler A: The pathological aspect of phosphorus and calcium deficiency in cattle. *Vet Rec* **11**:1143–1147, 1931.
199. Theiler A, Green HH, Du Toit PJ: Phosphorus in the live stock industry. *J Dep Agric South Africa* **8**:460–504, 1924.
200. Thompson KG: Bones and joints. In: Jubb, Kennedy, and Palmer's Pathology of Domestic Animals, ed. Maxie MG, 5th ed., pp. 1–184. Elsevier Saunders, Philadelphia, PA, 2007.
201. Thompson KG, Cook TG: Rickets in yearling steers wintered on a swede (*Brassica napus*) crop. *N Z Vet J* **35**:11–13, 1987.
202. Thompson KG, Dittmer KE, Blair HT, Fairley RA, Sim DFW: An outbreak of rickets in Corriedale sheep: evidence for a genetic aetiology. *N Z Vet J* **55**:137–142, 2007.
203. Thompson KG, Robinson BM: An osteodystrophy apparently caused by vitamin D deficiency in growing pigs. *N Z Vet J* **37**:155–157, 1989.
204. Thomson K, Morley R, Grover SR, Zacharin MR: Postnatal evaluation of vitamin D and bone health in women who were vitamin D–deficient in pregnancy, and in their infants. *Med J Aust* **181**:486–488, 2004.
205. Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, Gabizon D, Liberman UA: Hereditary hypophosphatemic rickets with hypercalciuria. *N Engl J Med* **312**:611–617, 1985.
206. van Abel M, Hoenderop JGJ, Dardenne O, St Arnaud R, van Os CH, van Leeuwen HJPTM, Bindels RJM: 1,25-Dihydroxyvitamin D₃-independent stimulatory effect of estrogen on the expression of ECaC1 in the kidney. *J Am Soc Nephrol* **13**:2102–2109, 2002.
207. van Abel M, Hoenderop JGJ, van der Kemp AWC, van Leeuwen JPTM, Bindels RJM: Regulation of the epithelial Ca²⁺ channels in small intestine as studied by quantitative mRNA detection. *Am J Physiol Gastrointest Liver Physiol* **285**:G78–G85, 2003.
208. Van Cromphaut SJ, Dewerchin M, Hoenderop JGJ, Stockmans I, Van Herck E, Kato S, Bindels RJM, Collen D, Carmeliet P, Bouillon R, Carmeliet G: Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. *Proc Natl Acad Sci U S A* **98**:13324–13329, 2001.
209. Van Saun RJ: Nutritional diseases of South American camelids. *Small Rumin Res* **61**:153–164, 2006.
210. Van Saun RJ: Vitamin D–responsive rickets in neonatal lambs. *Can Vet J* **45**:841–844, 2004.
211. Van Saun RJ, Smith BB, Watrous BJ: Evaluation of vitamin D status of llamas and alpacas with hypophosphatemic rickets. *J Am Vet Med Assoc* **209**:1128–1133, 1996.
212. Wang JT, Lin C-J, Burrige SM, Fu GK, Labuda M, Portale AA, Miller WL: Genetics of vitamin 1 α -hydroxylase deficiency in 17 families. *Am J Hum Genet* **63**:1694–1702, 1998.
213. Webb AR, Kline L, Holick MF: Influence of season and latitude on the cutaneous synthesis of vitamin D₃: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D₃ synthesis in human skin. *J Clin Endocrinol Metab* **67**:373–378, 1988.
214. Weisberg P, Scanlon KS, Li RW, Cogswell ME: Nutritional rickets among children in the United States: review of cases reported between 1986 and 2003. *Am J Clin Nutr* **80**:1697S–1705S, 2004.
215. Weisman Y: Vitamin D deficiency rickets and osteomalacia in Israel. *Isr Med Assoc J* **5**:289–290, 2003.

216. Wharton B, Bishop N: Rickets. *Lancet* **362**:1389–1400, 2003.
217. Whitfield GK, Selznick SH, Haussler CA, Hsieh J-C, Galligan MA, Jurutka PW, Thompson PD, Lee SM, Zerwekh E, Haussler MR: Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D₃: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. *Mol Endocrinol* **10**:1617–1631, 1996.
218. Whyte MP: Heritable forms of rickets and osteomalacia. In: *Connective Tissue and Its Heritable Disorders. Molecular, Genetic, and Medical Aspects*, ed. Royce PM, Steinmann B, pp. 765–787. Wiley-Liss, Inc, New York, NY, 2002.
219. Wilke R, Harmeyer J, von Grabe C, Hehrmann R, Hesch RD: Regulatory hyperparathyroidism in a pig breed with vitamin D dependency rickets. *Acta Endocrinol (Copenh)* **92**:295–308, 1979.
220. Wolf M, Thadhani R: Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. *Semin Dial* **18**:302–306, 2005.
221. Wu S, Finch J, Zhong M, Slatopolsky E, Grieff M, Brown AJ: Expression of the renal 25-hydroxyvitamin D-24-hydroxylase gene: regulation by dietary phosphate. *Am J Physiol Renal Physiol* **271**:F203–F208, 1996.
222. Yagci A, Werner A, Murer H, Biber J: Effect of rabbit duodenal mRNA on phosphate transport in *Xenopus laevis* oocytes: dependence on 1,25-dihydroxyvitamin-D₃. *Pflugers Arch* **422**:211–216, 1992.
223. Yagishita N, Yamamoto Y, Yoshizawa T, Sekine K, Uematsu Y, Murayama H, Nagai Y, Krezel W, Chambon P, Matsumoto T, Kato S: Aberrant growth plate development in VDR/RXR_γ double null mutant mice. *Endocrinology* **142**:5332–5341, 2001.
224. Yamaguchi A, Kohno Y, Yamazaki T, Takahashi N, Shinki T, Horiuchi N, Suda T, Koizumi H, Tanioka Y, Yoshiki S: Bone in the marmoset: a resemblance to vitamin D-dependent rickets, type II. *Calcif Tissue Int* **39**:22–27, 1986.
225. Yoshida T, Monkawa T, Tenenhouse HS, Goodyer P, Shinki T, Suda T, Wakino S, Hayashi M, Saruta T: Two novel 1 α -hydroxylase mutations in French-Canadians with vitamin D dependency rickets type I. *Kidney Int* **54**:1437–1443, 1998.
226. Zhong Y, Armbrecht HJ, Christakos S: Calcitonin, a regulator of the 25-hydroxyvitamin D₃ 1 α -hydroxylase gene. *J Biol Chem* **284**:11059–11069, 2009.
227. Zierold C, Mings JA, DeLuca HF: Regulation of 25-hydroxyvitamin D₃-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D₃ and parathyroid hormone. *J Cell Biochem* **88**:234–237, 2003.
228. Zierold C, Reinholz GG, Mings JA, Prahl JM, DeLuca HF: Regulation of the porcine 1,25-dihydroxyvitamin D₃-24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D₃ and parathyroid hormone in AOK-B50 cells. *Arch Biochem Biophys* **381**:323–327, 2000.
229. Zittermann A: Vitamin D in preventive medicine: are we ignoring the evidence? *Br J Nutr* **89**:552–572, 2003.